The sequence variability of viral structure polypeptides has been associated with immune escape mechanisms. The V1 region of simian immunodeficiency virus (SIV) is a highly variable region of the SIVmac env gene. Here, we describe the V1 region as a linear neutralizing epitope. V1 region-specific neutralizing antibodies (NAb) were first demonstrated in a rabbit infected with a recombinant vaccinia virus carrying the env gene of human immunodeficiency virus type 2 strain ben (HIV-2ben). Since we detected in this animal V1 region-specific NAb that were able to neutralize not only human immunodeficiency virus type 2 but also SIVmac32H, we investigated whether a similar immune response is evoked in macaques (Macaca mulatta) either infected with SIVmac or immunized with the external glycoprotein (gp130) of the same virus. Distinctly lower NAb titers were found in the SIVmac-infected animals than in the gp130-immunized macaques. Since the NAb titers in both groups were high enough for competition experiments, we used five overlapping peptides encompassing the whole V1 region for a detailed identification of the epitope. In each of the 12 macaques investigated, we detected a high level of NAb reacting with at least one peptide located in the central part of the V1 region. The relatively high degree of divergence, especially within the central part of the V1 region, which characterized the evolution of the retroviral sequences from the original inoculum in the infected macaques suggests the development of escape mutants. Furthermore, 3 of 12 animals developed NAb directed against the amino-terminal end of the V1 region epitope. Sequence analysis, however, revealed relatively low levels of genetic drift and genetic variability within this part of the V1 region. The induction of V1 env-specific NAb not only in gp130-immunized macaques but also in SIVmac-infected animals in combination with the increased genetic variability of this region in vivo indicates a marked biological significance of this epitope for the virus.
The identification of epitopes inducing either protective immunity or retardation of disease progression is crucial for AIDS vaccine development. Simian immunodeficiency virus (SIV) is related to both human immunodeficiency virus (HIV) type 1 (HIV-1) and HIV-2 and causes AIDS in several macaque species. Therefore, SIV has been used extensively as a model for HIV infection, pathogenesis, and vaccine development (8) .
Although several studies with macaques have demonstrated the feasibility of SIV vaccines, no significant correlation between protection and any specific parameter of humoral or cellular immunity has been described so far. In the model systems, however, passive transfer of antibodies mediated protection against infection with HIV or SIV. Passive transfer of neutralizing monoclonal antibodies directed against the HIV-1IIIB V3 region into chimpanzees (9, 10) or of immune sera collected from SIVsm-infected macaques into other macaques (49) prevented HIV or SIVsm infection, respectively. Similarly, transfer of sera from monkeys immunized with SIVmne peptides protected against SIVmne infection (32) . However, more recently, Kent et al. (27) failed to protect cynomolgus monkeys (Macaca fascicularis) against an SIV challenge performed after transfusion of SIV-neutralizing murine monoclonal antibodies.
Rhesus monkeys immunized with oligomeric native external glycoprotein gp130 developed high-titer SIVmac neutralizing antibodies (NAb) correlating to some extent with the protection rate observed after homologous challenge (34) . The external glycoprotein will certainly be an important component of an HIV AIDS vaccine, since it is a major target for NAb. Moreover, the HIV-1 env gene displays a high degree of genetic variability, probably leading to the evolution of viral variants capable of evading the host's immune response. The genetic variation of the env gene between different virus isolates is believed to be the major obstacle for developing an efficient vaccine against a broad spectrum of distinct immunodeficiency virus isolates. Several linear and conformation-dependent neutralization determinants on the HIV-1 envelope glycoprotein have been characterized (6, 11-13, 17-19, 25, 40, 41, 45, 52, 58, 65) . Among these, a presumed loop structure within the V3 region has been reported as the major neutralization epitope (13, 19, 45, 52) . In contrast to the linear neutralizing sites found within the V3 region of HIV-1, the principal neutralizing determinant of SIVmac251 is described as conformation dependent and was mapped on the carboxy-terminal half of gp130 (20, 21) . Although a linear neutralization determinant corresponding to the V3 region of HIV-1 has not been detected for SIV in previous studies (20, 26, 50) , in a recently published report (46) a linear neutralizing epitope located in the carboxy-terminal part of the V3 domain of SIVmac251 gp130 was identified. Further linear SIV neutralization epitopes in the V2 region (3, 26, 37) , the V4 region (2, 61) , and the variable region of the transmembrane glycoprotein (27) have been described.
We have analyzed the V1 env region of SIVmac since its sequence variations might be responsible for viral escape mutants in vaccinated macaques, as discussed recently (1) . A correlation between disease progression to simian AIDS and emergence of certain mutations in the V1 region of the SIV env gene has already been demonstrated (43, 44) . Recent studies confirm and extend these observations for HIV-2 in macaques (60). Since we have discovered a V1 env epitope inducing HIV-2ben and SIVmac32H cross-neutralizing antibodies in a rabbit, we examined the influence of the V1 region on the development of NAb in vaccinated and SIVmac-infected rhesus monkeys. Therefore, we have analyzed the antibody response to linear antigenic determinants of SIV gp130 by NAb inhibition with five overlapping 20-mer peptides derived from the V1 region of SIVmac251.
MATERIALS AND METHODS

Cells and viruses.
The neutralizing capacities of rabbit and macaque sera against HIV-2ben (54) and SIVmac32H (7) were measured. HIV-2ben was propagated in Molt-4 clone 8 cells (28) , and SIVmac32H was propagated in MT-2 cells (39) . The cell lines were kept in RPMI 1640 medium (Gibco, Karlsruhe, Germany) supplemented with 10 or 20% fetal calf serum and antibiotics. Cultures were grown at 37°C in a water-saturated atmosphere containing 6% CO 2 .
Rabbit sera. Antisera directed against the carboxy-terminal region of the HIV-2ben glycoprotein were obtained from a small Russian rabbit (R140) that was infected with a recombinant vaccinia virus (rVV 198) expressing a C-terminally truncated env gene fragment (42) of the HIV-2ben clone MK6 (29) . rVV 198 expressed the amino terminus of gp120 up to amino acid 198, including the V1 and V2 regions of the external glycoprotein. The protocol for infection was described previously by Schäffner et al. (53) .
Monkey sera. To investigate the development of SIVmac NAb and V1 regionspecific NAb, we examined either SIVmac-infected rhesus monkeys (Macaca mulatta) or monkeys immunized with a preparation of oligomeric gp130 from the same virus strain (see Table 1 ).
Five monkeys (Mm1696, Mm1703, Mm1708, Mm5132, and Mm6266) were infected with either SIVmac32H or SIVmacMPBMC as described recently (56, 62) . NAb in sera were determined 52 weeks after infection.
Seven macaques were immunized with oligomeric gp130. Mm1774, Mm1777, Mm1795, and Mm1796 were immunized four times with 100 g of gp130 oligomers mixed with RIBI (supplied by RIBI Immunochemical Research Corporation, Hamilton, Mont.) as an adjuvant. Mm1698, Mm1701, and Mm1715 were immunized seven times with 100 g of gp130 oligomers mixed with keyhole limpet hemocyanin and incomplete Freund's adjuvant (35, 36) .
Neutralization test. HIV-2ben and SIVmac32H NAb in serum were measured by MT-4 assay, which is well established for in vitro evaluation of anti-HIV agents either by colorimetric monitoring (47) or by monitoring with radioactively labelled thymidine (16, 22, 23) , as well as for measurement of NAb against HIV-related viruses (15, 24, 33, 57, 59, 64) . Titers of NAb either against cell-free supernatant of HIV-2ben-infected Molt-4 clone 8 cells or against cell-free supernatant of SIVmac32H-infected MT-2 cells were determined. The MT-4 cell assay was performed with flat-bottom 96-well microtiter plates. During cultivation, MT-4 cells were grown in RPMI 1640 medium containing 25 mM HEPES buffer (pH 6.5) and 10% fetal calf serum. Heat-inactivated (56°C, 30 min) monkey sera were tested in triplicate serial twofold dilutions starting with 1:10. The sera were incubated with 100 50% tissue culture infective doses of the respective virus. After 1 h of incubation at 37°C, 3 ϫ 10 4 MT-4 cells were added to each well. Fresh medium was added to each well 3 days after infection. Four days after infection, 0.1 Ci of [ 3 H]thymidine (Amersham, Braunschweig, Germany) was added per well. Twenty hours later, the [ 3 H]thymidine incorporation into the cellular DNA was determined. Neutralization was defined as 75% reduction of virus-induced cell death.
Peptide inhibition of neutralization. Five overlapping peptides derived from the V1 env region of SIVmac251 (38) were obtained from the AIDS Reagent Project, Medical Research Council. Peptide 9 contains the carboxy-terminal end of constant region 1 (C1) and the amino-terminal end of V1. Peptides 10, 11, and 12 comprise the V1 region, and peptide 13 represents the carboxy-terminal end of V1 and the amino-terminal end of V2 (Fig. 1) . Two peptides (peptides 1 and 2) encompass the whole V1 region of HIV-2ben and correspond to SIV peptides 10 and 12, respectively. The competition of NAb with peptides was carried out according to an established method described previously (4) . Before their use in neutralization assays, as described above, triplicate serum dilutions were preincubated with 4 g of each peptide in a final volume of 30 l for 2 h at 37°C. A reduction in the neutralizing capacity of a serum sample indicates that the respective peptide was able to block the corresponding NAb. To demonstrate specificity, the general absorptive effect of peptides on NAb was demonstrated by incubating equal volumes of antisera with a negative-control peptide. Furthermore, each inhibition assay was done twice, thus leading to a total of six samples of each dilution examined in parallel.
Sequencing of the V1 region. Proviral sequences in the original inoculum that was used for infection as well as in monkey peripheral blood mononuclear cells (MPBMC) obtained 52 weeks after infection were determined. The V1 region was amplified and sequenced. About 1 g of DNA was added to each PCR mixture. The following primer pairs were used for amplification: 5Ј GACCTCA ATAAAGCCTTGTG 3Ј (nucleotides 6864 to 6884) and 5Ј GCATAAGGAGG TGCAC 3Ј (nucleotides 7282 to 7301). PCR amplification was performed in the presence of 3 mM Mg 2ϩ , 0.1% Triton X-100, the four deoxynucleoside triphosphates (200 mM each), 25 pmol of each oligonucleoside primer, and 1 U of Taq polymerase (GIBCO/BRL, Eggenstein, Germany). A total of 35 cycles were run with the following profile: denaturation for 30 s at 95°C, annealing for 60 s at 52°C, and polymerization for 30 s at 72°C. An initiating ramp for 2 min at 95°C and a final elongation step for 15 min at 72°C were added. The amplification products were purified by electrophoresis on a 2% agarose gel and extracted from the agarose. The cloned products were sequenced according to the protocols of the manufacturer (Amersham). 
RESULTS
The amino-terminal region of HIV-2 gp130 induces V1-specific antibodies capable of neutralizing HIV-2 as well as SIVmac in rabbits. NAb directed against the V1 regions of HIV-2 and SIVmac were first identified in a rabbit (R140) immunized with a vaccinia virus construct (rVV 198) expressing 198 amino acids of the amino terminus of HIV-2ben gp120, including the C1, V1, and V2 regions. This rabbit developed antibody titers of 10 5 against HIV-2 and SIVmac as determined by enzyme-linked immunosorbent assay (data not shown). Sera of this rabbit were further investigated for NAb directed against HIV-2ben and SIVmac32H, both belonging to the closely related HIV-2/SIVmac group. The rabbit's preimmune serum did not show any NAb against HIV-2 or SIVmac. HIV-2 and SIVmac were neutralized at titers of 640 and 320, respectively (Table 1) . In recent studies, peptide enzyme-linked immunosorbent assays showed that V1 regionspecific antibodies were present in SIVmac-infected macaques (38, 63) , and this region was even proposed as a neutralization epitope (1) . Therefore, we were interested in determining whether peptides spanning the V1 region were capable of absorbing the neutralizing activity of this rabbit serum. The absorption test was carried out according to a recently published protocol that was successfully applied to characterize the V3 region of HIV-1 as a neutralization epitope (4). Sera of R140 were therefore absorbed with HIV-2ben-or SIVmacspecific V1 peptides and then tested for neutralizing activity. In repeated experiments, no competition of NAb was found with HIV-2-specific peptide 1 and SIVmac-specific peptide 10, either in the presence of HIV-2ben or in the presence of SIVmac32H. In contrast, HIV-2-specific peptide 2 and SIVmacspecific peptide 12, which overlaps a region with substantial homology between the two viruses (Fig. 2) , absorb a high percentage of NAb (Table 1) . With HIV-2-specific peptide 2, approximately 93% of the homologous HIV-2ben NAb titer was competed, from 640 to 40, and a competition of 75% from 320 to 40 was found with SIVmac32H. The same absorption experiments were subsequently performed with SIVmac-specific peptide 12. This peptide competed 75% of the NAb directed against HIV-2ben or SIVmac32H.
V1 peptides absorb NAb from SIV-infected and gp130-immunized macaques. Before determining their epitope specificities, we quantified the NAb within two groups of rhesus macaques. The animals of the first group were infected with SIVmac32H or SIVmacMPBMC, and those of the other group were immunized with gp130 oligomers of SIVmac32H. The SIVmac32H NAb titers of the examined animals are summarized in Table 2 . In general, the five infected animals had developed moderate NAb titers of between 80 and 320 at 52 weeks after infection, whereas all macaques that had been immunized with the gp130 oligomers developed higher NAb titers of between 1,280 and 5,120. Preimmunization or preinfection serum samples did not show any neutralizing activity against SIVmac32H.
The influence of V1 peptides on the NAb titer is shown for one representative animal in Fig. 3 . Without peptide competition, the serum of this animal (Mm5132) neutralized SIVmac32H even when diluted 1:160. The presence of either peptide 9 or peptide 13, representing the flanking regions of the amino-and carboxy-terminal ends of the V1 region, respectively, did not influence the NAb titer. In contrast, peptides 11 and 12 each reduced the titer from 160 to 40. Moreover, the greatest competition was found with peptide 10, which reduced the NAb titer to 20.
The results for the five SIV-infected and seven gp130-immunized animals obtained in the competitive MT-4 cell assay are summarized in Table 2 . In general, peptides 9 and 13 did not reduce the NAb titers of any of the sera tested. Peptide 10 absorbed the NAb in two of five infected macaques and one of seven immunized macaques; an 87.5% competition was observed in infected animal Mm5132 and the immunized macaque Mm1774, and a reproducibly lower competition was found in infected macaque Mm6266. Competition by peptide 11 of 75 and 50% was found in infected animals Mm5132 and Mm1703, respectively. Competition by peptide 11 was also found in sera from four of seven immunized macaques. The neutralizing activity in these animals could be reduced by between 50 and 87.5%. However, the greatest reactivity among all tested animals was found with peptide 12. NAb from five of five infected and five of seven immunized macaques interacted with peptide 12. Peptide 12 absorbed between 50 and 87.5% of the NAb of these animals.
Competition of neutralization by SIVmac-specific V1 peptide 12 correlates with a high degree of genetic variation within the corresponding proviral region. To investigate whether an increase in variability within the proviral V1 region of SIVmac32H- a NAb titers in the absence and in the presence of the indicated peptides. Twofold serial dilutions of sera up to 1:10 were tested. Each NAb titer is the mean for six serum samples examined in parallel. All 10 mean values have a standard deviation of 0.00.
b The NAb titer of serum was defined as the serum dilution able to inhibit 75% of virus-induced reduction of [ infected monkeys might contribute to subdue the NAb directed against V1, the V1 env sequences of five infected monkeys (Mm1696, Mm1703, Mm1708, Mm5132, and Mm6266) were analyzed. Proviral sequences obtained 52 weeks after infection were compared to the sequence of the maternal virus used for infection (Fig. 4) .
In the part of the V1 env region that is represented by peptide 10, the proviruses of all five macaques reisolated after 52 weeks of infection differed only slightly from the SIVmac32H respective to the SIVmacMPBMC virus sequences of the inoculum. Despite a reduction in neutralization by peptide 10 in sera from Mm5132 and Mm6266 but not in serum from Mm1708, the proviral sequences of all three monkeys had evolved in the same direction. The proviral sequence encompassing the overlapping region of peptides 11 and 12 developed a high degree of variation, whereas the regions outside the overlapping part showed only minor variation. However, peptide 11 was able to reduce neutralization only in one case, whereas peptide 12 could reduce neutralization in five of five animals. In general, the sequences of the V1 clones homologous to peptides 9 and 13, which represent the amino-and carboxy-terminal ends of the V1 region, respectively, and which overlap with the adjacent C1 or V2 region, were highly conserved. In spite of the great homology, peptides 9 and 13 had no competitive influence on the NAb titers of the four macaques investigated.
DISCUSSION
In this report, we describe the detection of a linear neutralizing epitope found in the V1 env region of HIV-2ben and SIVmac32H. The immunization of a rabbit with rVV 198, expressing a C-terminally truncated gp120 fragment of HIV-2ben comprising the C1, V1, and V2 regions, gave rise to NAb which cross-neutralized HIV-2ben as well as SIVmac32H. NAb in the sera of this animal could be absorbed by V1 peptides specific for HIV-2ben and SIVmac32H. So far, no linear target for NAb has been described, either for HIV-2 or for SIVmac. After the initial observation that at least a certain part of this region plays a role as a linear neutralizing epitope in rabbits, we concentrated our further studies on SIVmac-infected and SIVmac gp130-immunized macaques, a well-established model for vaccine development (7, 35, 36, 57) . Despite their well-described immunogenicity (48, 55, 63) , the epitopes within peptide 9-and peptide 13-homologous V1 env regions did not give rise to NAb. A strong humoral immune response to peptide 10, as previously reported (55, 63) , was found in sera from SIVmac32H-infected monkeys, which regularly develop AIDS-like symptoms soon after infection, but not in sera from HIV-2ben-preinfected and SIVmac32H-superinfected macaques, which showed retarded disease progression (48) . Despite the induction of NAb directed against the V1 env region homologous to peptide 10 in infected macaques, the corresponding proviral sequences isolated from their MPBMC showed only a minor degree of genetic variation. In confirmation of this, it has previously been demonstrated that especially the region corresponding to peptide 10 within V1 env is of low genetic diversity (1). Thus, it seems that despite the presence of NAb directed against peptide 10, it is not necessary for the infecting virus to escape this immune response by an increased variability. Immunized and infected macaques could not be discriminated by the absorption of their NAb to peptides 11 and 12. In our study, only two of five SIVmac-infected monkeys and four of seven gp130-immunized macaques had developed NAb to peptide 11, whereas sera from 10 of 12 monkeys contained NAb that could be absorbed by peptide 12. We believe that the interindividual differences in reactivity to this region represented by the absorption of NAb by V1-specific peptides as demonstrated above are due to the host's specific major histocompatibility complex class II background and/or to virus-specific mechanisms such as in vivo V1 region variability. More studies are needed to further characterize this region and the epitopes therein. Even though our data did not reveal concordant viral sequence evolution in vivo, sequence analyses of proviral V1 regions of five infected macaques suggest that this region, in particular the peptide 11 and 12 overlapping sequence, was altered in vivo under the pressure of NAb. This finding confirms other studies in which the highest degree of variation within the V1 region of SIV was demonstrated for the region homologous to peptides 11 and 12 (5, 51, 55) . Further studies will have to determine whether the increased variability in the peptide 11 and 12 overlapping region has led to a loss of NAb capable of binding to peptides 11 and 12.
It has been well described that the principal neutralization determinant of HIV-1 is located within the third variable domain (V3) of the external glycoprotein gp120 (13, 31, 45, 52) . For SIV, a conformation-dependent principal neutralization determinant was shown (14, 20, 21) . However, Palker and coworkers (46) found a linear neutralizing epitope located in the carboxy-terminal part of the SIVmac251 gp130 V3 region by immunizing goats with V3-specific peptides. This neutralizing site within V3, however, was not recognized by sera from SIVmac251-infected rhesus macaques. In contrast to these data, the linear neutralizing epitope within the V1 region described here proved to be highly immunogenic in vaccinated as well as in SIVmac-infected rhesus macaques. In our study, V1 peptides considerably suppressed the SIVmac32H-neutralizing activity. In SIVmac32H-infected monkeys, which had developed only a moderate SIVmac32H NAb response, the titers decreased by 50 to 87.5%. The high NAb titers that had been detected in gp130-immunized animals were reduced at approximately the same rate of 50 to 75%. Therefore, we can conclude that a large portion of the NAb is directed against the SIVmac32H V1 region, and we propose this region as a dominant linear neutralizing epitope.
